Neuromodulation
Neurostimulation treatments aim to reduce seizures by changing activity within seizure-related brain networks. Different systems stimulate different targets, work in different ways and are not available in the same way in every country.
Central point: DBS, RNS and VNS are different treatments. None should be described as a universal next step for drug-resistant epilepsy, and local approval and availability must be checked.
Deep brain stimulation (DBS)
DBS uses surgically implanted electrodes connected to a pulse generator. For epilepsy, a common target is the anterior nucleus of the thalamus, part of a network involved in seizure propagation. Stimulation is programmed to run according to set parameters rather than waiting for a detected seizure.
NICE has HealthTech guidance on DBS for refractory epilepsy in adults. NICE describes it as an option for some people with medically refractory epilepsy when resective surgery is not indicated, but stresses the need for specialist patient selection and appropriate governance. In the United States, the FDA indication for anterior thalamic DBS applies to selected adults with drug-resistant focal-onset seizures under defined criteria.
Responsive neurostimulation (RNS)
RNS is a closed-loop system. Electrodes record electrical activity from one or two identified seizure foci and the implanted device delivers stimulation when programmed patterns are detected. This is different from continuously or intermittently stimulating a network target such as the thalamus.
The NeuroPace RNS System has FDA approval in the United States for selected adults with drug-resistant focal-onset seizures arising from no more than two localised epileptogenic foci. Availability outside the United States is more limited and should never be assumed from US approval alone. People in the UK need advice from a tertiary epilepsy centre about which neurostimulation treatments are actually commissioned and available to them.
How are DBS and RNS different from VNS?
VNS stimulates the vagus nerve in the neck and influences brain networks indirectly. DBS stimulates a deep brain target directly. RNS records cortical or depth-electrode activity at identified seizure foci and responds to detected patterns. These differences affect who may be considered for each treatment, the surgery required and how the device is programmed.
Who might be considered?
Neurostimulation is generally considered in drug-resistant epilepsy when medication has not achieved adequate seizure control and curative or resective surgery is unsuitable, too risky or unlikely to succeed. The exact pathway depends on seizure type, localisation, imaging, previous surgery, age, comorbidities and local service availability.
What does the evidence show?
Systematic review evidence assessed by the ILAE shows that VNS, DBS and RNS can all reduce seizure frequency in selected people with drug-resistant epilepsy, with response often improving over longer follow-up. However, studies differ in design, population and outcome definitions. Reduction in seizures is a more realistic population-level expectation than guaranteed seizure freedom.
Risks and practical issues
Risks can include infection, bleeding, hardware problems, pain and the risks associated with intracranial surgery. Depending on the device and target, stimulation can also affect mood, cognition or other neurological functions. Batteries or generators may require future replacement, and regular specialist programming is part of treatment.
MRI access also depends on the exact device and manufacturer conditions. Anyone with an implanted neurostimulation system should tell radiology staff before MRI and should carry device information where possible.
Neurostimulation is not the same as epilepsy surgery aimed at cure
Resective or ablative epilepsy surgery may aim for seizure freedom by treating the seizure-generating tissue. Neuromodulation is usually palliative: the aim is to reduce seizure frequency, severity or burden when the seizure network cannot be safely removed or disconnected.
Related pages
Vagus Nerve Stimulation · Epilepsy Surgery and Presurgical Assessment · Drug-Resistant Epilepsy · Treatment Options
Deep brain stimulation
Deep brain stimulation delivers scheduled electrical stimulation through implanted electrodes. For epilepsy, the anterior nucleus of the thalamus is the best-established target in adults with drug-resistant focal epilepsy in jurisdictions where it is approved. Benefit typically accumulates over time rather than appearing immediately after implantation.
Responsive neurostimulation
Responsive neurostimulation records electrical activity continuously and delivers stimulation when patterns associated with seizures are detected. It is used mainly for selected people with one or two focal seizure-onset regions that cannot be safely removed. Availability remains highly country-dependent.
Other targets and approaches
Centromedian thalamic stimulation, closed-loop thalamic approaches and other targets are being studied for generalised, multifocal and network epilepsies. Evidence is evolving and not all approaches are standard or licensed.
These devices are not interchangeable
DBS, RNS and VNS differ in anatomy, recording capability, programming, evidence base and regulatory status. Choice depends on seizure network, previous surgery, MRI findings, cognitive and psychiatric factors, and access to specialist centres.
Long-term management
Neuromodulation requires repeated programming, battery or generator management and ongoing epilepsy review. It is usually used to reduce seizure burden rather than presented as a guaranteed route to seizure freedom.
Sources
NICE HTG550 — Deep brain stimulation for refractory epilepsy in adults
ILAE Surgical Therapies Commission — Neurostimulation in drug-resistant epilepsy
US FDA — NeuroPace RNS System approval information
US FDA — DBS therapy for epilepsy approval information
This page provides general educational information and is not individual medical advice. Device approval, eligibility and availability vary by country and service.
Evidence checked: September 2026.